Physician

Quoc V Truong, MD

According to 2025 Medicare claims, Quoc Truong, MD (NPI: 1518922814) practices hematology/oncology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67208-3006. Truong is affiliated with the Aledade 155 National MSSP (ACO ID: A5358), CoreHealth Alliance LLC (ACO ID: A5645), and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Truong's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,273 traditional Medicare patients, billed 416,773 HCPCS/CPT codes, and received $7,191,127 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,594 prescription claims across 361 beneficiaries totaling $4,173,134 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 24 claims. Open Payments data shows 296 records totaling $62,886. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,272,062 to $7,191,127. Similarly, Part D prescription costs have risen steadily, from $866,817 to $4,173,134. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,701 to $2,375.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	672	167,777	$2,272,062
2016	716	291,030	$3,002,546
2017	827	327,302	$3,608,520
2018	1,203	407,494	$4,480,456
2019	1,065	482,519	$5,194,528
2020	934	412,717	$4,919,191
2021	850	451,524	$5,143,431
2022	897	393,828	$4,483,154
2023	1,176	383,709	$5,487,636
2024	1,273	416,773	$7,191,127

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	155	938	$866,817
2016	221	1,710	$2,137,735
2017	265	1,878	$2,659,551
2018	293	1,989	$2,361,181
2019	329	2,368	$4,077,429
2020	357	2,509	$3,935,457
2021	369	2,324	$3,425,901
2022	351	2,402	$3,165,981
2023	351	2,649	$3,795,975
2024	361	2,594	$4,173,134

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	148	$21,142
2016	N/R	N/R	N/R
2017	N/R	23	$5,818
2018	N/R	16	$301
2019	N/R	48	$5,344
2020	N/R	47	$4,620
2021	N/R	96	$5,763
2022	N/R	86	$3,053
2023	N/R	52	$12,757
2024	N/R	24	$862

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	345	483	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	322	625	$12
36415	Insertion of needle into vein for collection of blood sample	327	1,732	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	323	1,571	$6
85007	Microscopic examination for white blood cells with manual cell count	323	1,573	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	62	1,533	$768,577
Imbruvica	Ibrutinib	24	672	$392,095
Ibrance	Palbociclib	23	644	$335,765
Brukinsa	Zanubrutinib	18	540	$257,209
Jakafi	Ruxolitinib Phosphate	21	630	$193,249

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	11	$617
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$245

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	296	$62,886	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Quoc V. Truong, MD?

Tedicare shows public-source Medicare data for Quoc V. Truong, MD (NPI 1518922814), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Quoc V. Truong, MD have ACO affiliation data?

Quoc V. Truong, MD is shown with ACO affiliation data for Aledade 155 National MSSP (MSSP, ACO ID A5358), CoreHealth Alliance LLC (MSSP, ACO ID A5645), and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Quoc V. Truong, MD?

Quoc V. Truong, MD is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Quoc V. Truong, MD have Open Payments data?

Quoc V. Truong, MD has 296 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.